Cargando…

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

The outcomes of patients with multiple myeloma (MM) refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) remain poor. In this study, we performed whole genome and transcriptome sequencing of 39 heavily pretreated relapsed/refractory MM (RRMM) patients to identify mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giesen, Nicola, Paramasivam, Nagarajan, Toprak, Umut H., Huebschmann, Daniel, Xu, Jing, Uhrig, Sebastian, Samur, Mehmet, Bähr, Stella, Fröhlich, Martina, Mughal, Sadaf S., Mai, Elias K., Jauch, Anna, Müller-Tidow, Carsten, Brors, Benedikt, Munshi, Nikhil, Goldschmidt, Hartmut, Weinhold, Niels, Schlesner, Matthias, Raab, Marc S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Plasma Cell Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335090/ https://www.ncbi.nlm.nih.gov/pubmed/35045690 http://dx.doi.org/10.3324/haematol.2021.279360

Ejemplares similares

Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment
por: Soncini, Debora, et al.
Publicado: (2021)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way
por: Giannandrea, Domenica, et al.
Publicado: (2022)

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
por: Taiana, Elisa, et al.
Publicado: (2022)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis
por: Mangiacavalli, Silvia, et al.
Publicado: (2022)

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence
por: Holler, Maximilian, et al.
Publicado: (2022)

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
por: Lawless, Sarah, et al.
Publicado: (2022)

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to low-dose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex
por: Zhou, Xiang, et al.
Publicado: (2023)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
por: Schavgoulidze, Anaïs, et al.
Publicado: (2022)

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023)

IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders
por: Bruehl, Frido K., et al.
Publicado: (2023)

Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
por: Puertas, Borja, et al.
Publicado: (2023)

Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs
por: Takamatsu, Hiroyuki, et al.
Publicado: (2023)

Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study
por: McCurdy, Arleigh, et al.
Publicado: (2023)

IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma
por: Pisano, Michael D., et al.
Publicado: (2023)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
por: Sigurbergsdóttir, Aðalbjörg Ýr, et al.
Publicado: (2023)

Accurate and efficient detection of gene fusions from RNA sequencing data
por: Uhrig, Sebastian, et al.
Publicado: (2021)

Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma
por: Niazi, Yasmeen, et al.
Publicado: (2022)

Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancer
por: Ishaque, Naveed, et al.
Publicado: (2018)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (1991)

Plasmas en todas partes /
por: Bravo, Silvia
Publicado: (2001)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Correction to: Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
por: Simon, Malte, et al.
Publicado: (2022)

Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations
por: Simon, Malte, et al.
Publicado: (2021)

Distributed Ledger Technology in genomics: a call for Europe
por: Thiebes, Scott, et al.
Publicado: (2019)

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials
por: Kauer, Joseph, et al.
Publicado: (2023)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Characterization of rare germline variants in familial multiple myeloma
por: Catalano, Calogerina, et al.
Publicado: (2021)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Diffuse large B-cell lymphoma: An institutional analysis
por: Gogia, Ajay, et al.
Publicado: (2018)

Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol
por: Patekar, Mukesh, et al.
Publicado: (2018)

PNEUMOMEDIASTINUM AND PNEUMOTHORAX DUE TO NONINVASIVE POSITIVE PRESSURE VENTILATION IN COVID-19 PNEUMONIA
por: Thetford, Jay, et al.
Publicado: (2020)

Physics of fully ionized gases /
por: Spitzer, Lyman, 1914-1997
Publicado: (2006)

Plasmas-laboratory and cosmic
por: Boley, Forrest I.
Publicado: (1966)

Plasma physics.
por: Linhart, J. G.
Publicado: (1961)

Cannot write session to /tmp/vufind_sessions/sess_4b70e5qb96l7ojrt7clt25ehnu